Pfizer, BioNTech Final Analysis Says Vaccine Has 95% Efficacy
The biopharmaceutical company Pfizer Inc. and the immunotherapy company BioNTech have revealed good news yesterday (Wednesday), November 18, 2020. These two companies that jointly worked for the vaccine candidate BNT162b2 said in an announcement that after conducting the final efficacy analysis in their ongoing Phase 3 study, their vaccine candidate met all of the study’s primary efficacy endpoints.
Based on the analysis of the data, the companies’ mRNA-based COVID-19 vaccine candidate, BNT162b2, has an efficacy rate of 95% in participants without prior infection and also in participants with and without prior infection.
“Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group.”
– Pfizer Inc., November 18, 2020
According to Pfizer, efficacy was consistent across age, gender, race and ethnicity demographics. In adults over the age of sixty five (65), the efficacy they have observed was over 94%. No serious safety concerns related to the vaccine have been reported by Data Monitoring Committee to date.
Moreover, Pfizer Inc. and BioNTech also announced that they have already achieved the safety milestone required by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). The companies are planning to submit a request to the FDA for a EUA within days.
What Pfizer Inc. and BioNTech CEOs Have to Say
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world. With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
– Dr. Albert Bourla, Pfizer Chairman and CEO
“We are grateful that the first global trial to reach the final efficacy analysis mark indicates that a high rate of protection against COVID-19 can be achieved very fast after the first 30 µg dose, underscoring the power of BNT162 in providing early protection.”
– Ugur Sahin, M.D., CEO and Co-founder of BioNTech
Another Vaccine Candidate shows 94.5 % Efficacy
Prior to Pfizer Inc. and BioNTech’s announcement, Moderna, Inc., a biotechnology company, have also recently unveiled that its vaccine candidate, mRNA-1273, for coronavirus in its phase 3 study met statistical criteria with a vaccine efficacy of 94.5%.
For More News and Updates
Keep up with what’s happening within and beyond the City of Baguio. Feel free to explore our Baguio City Guide website and our Baguio City Guide Facebook page to catch more news and updates.
Source: Pfizer Inc.